Nucleus Genomics is a New York-based consumer genomics company that sells a $399 at-home, clinical-grade whole-genome sequencing kit and a software platform that turns a person's full DNA sequence into readable reports on disease risk, carrier status, traits, and longevity. Founded in 2021 by Thiel Fellow Kian Sadeghi, Nucleus pairs whole-genome data with polygenic risk scores and lifestyle inputs to estimate risk for common, complex conditions. In 2025 it expanded into reproductive products - carrier screening, partner DNA alignment, and a controversial embryo-ranking tool, Nucleus Embryo - that put the company at the center of a public debate over the science and ethics of genetic selection.
Helix is a San Mateo-based population genomics company that helps health systems, life sciences companies, and public health organizations weave genomic data into everyday patient care. Built around its proprietary Exome+ assay and the first FDA-authorized whole exome sequencing platform, Helix powers large-scale precision health programs at partners like Mayo Clinic and Renown Health, with a research network spanning hundreds of thousands of sequenced participants.
Kardigan is a South San Francisco heart health company modernizing cardiovascular drug development. Founded by the team behind MyoKardia, it pairs a late-stage clinical pipeline in dilated cardiomyopathy, acute severe hypertension and calcific aortic valve stenosis with a 'cardiac intelligence' platform - real-world patient data and AI - to match disease drivers to the right responders.
Fred Parietti (Federico) is the Co-Founder and CEO of Multiply Labs, a San Francisco-based robotics company building automated biomanufacturing infrastructure for next-generation pharmaceuticals. Armed with a PhD in robotics from MIT and a childhood passion for Legos, he bet his career on a contrarian thesis: that the highest-value application for advanced robotics wasn't pizza delivery or self-driving cars, but cell therapy manufacturing — where a single batch is worth $400K to $2 million and still made by hand. Multiply Labs has raised over $25 million and announced an $85 million partnership with Retro Biosciences, positioning itself to slash cell therapy costs by 70% and bring life-saving treatments to millions instead of thousands.